Actively Recruiting
Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study
Led by University of Glasgow · Updated on 2026-04-13
90
Participants Needed
6
Research Sites
226 weeks
Total Duration
On this page
Sponsors
U
University of Glasgow
Lead Sponsor
N
NHS Greater Clyde and Glasgow
Collaborating Sponsor
AI-Summary
What this Trial Is About
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised milkshakes. However, treatment with biologics is only successful in approximately 55-60%. The liquid-only diet also has a better safety and effectiveness profile than traditional treatments like steroids. However, gut inflammation often returns not long after the normal diet is re-introduced, and it is difficult for patients to stick to as their sole source of nutrition for 6-8 weeks. The BIOPIC-Kids study aims to investigate whether replacing the normal diet with specialised milkshakes for 6 weeks improves response to treatment and maintenance of remission with biologics in children and young adults with CD. To achieve this, children and young adults (aged 6-18 years) with active CD commencing biologics as standard of care treatment will be randomly allocated to follow their normal diet OR replace varying amounts of their normal diet with specialised milkshakes for 6 weeks. Participants not wanting to be randomised can choose the group of their preference. Patients starting a liquid-only diet OR biologics alongside a liquid-only diet as standard of care treatment will also be recruited to compare different treatment outcomes.
CONDITIONS
Official Title
Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children or young adults aged 6 to 18 years with active Crohn's disease defined by a weighted paediatric Crohn's Disease Activity Index score 212.5 or faecal calprotectin level over 250 mg/kg
- Clinical indication to start standard induction treatment with TNF alpha inhibitors infliximab or adalimumab
- For observational groups, children or young adults aged 6 to 18 years with active Crohn's disease starting exclusive enteral nutrition therapy with or without TNF alpha inhibitors
You will not qualify if you...
- Unable to provide consent to participate (including young adults aged 16-18 unable to consent or carers unable to consent for children aged 6-15)
- Presence of stoma or short bowel syndrome
- Currently taking oral or intravenous steroids above 20mg/day prednisolone or 9mg/day budesonide
- Started another induction therapy or changed immunomodulator dose within past 4 weeks
- Crohn's disease with major fistulising or symptomatic fibrotic stricturing phenotype
- Comorbid anorexia nervosa
- Clinical contraindication to exclusive or partial enteral nutrition
- Positive test for blood-borne viruses such as HIV or Hepatitis B or C
- Untreated latent or active tuberculosis
- Currently enrolled in other studies involving investigational products or dietary interventions
- Food allergies preventing participation (e.g., cow's milk allergy)
- Pregnant or breastfeeding individuals
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The Royal Aberdeen Children's Hospital
Aberdeen, United Kingdom, AB25 2ZG
Not Yet Recruiting
2
University Hospital Crosshouse
Crosshouse, United Kingdom, KA2 0BE
Not Yet Recruiting
3
Ninewells Hospital
Dundee, United Kingdom, DD1 9SY
Not Yet Recruiting
4
Royal Hospital for Children & Young People
Edinburgh, United Kingdom, EH16 4TJ
Actively Recruiting
5
Royal Hospital For Children
Glasgow, United Kingdom, G51 4TF
Actively Recruiting
6
University Hospital Wishaw
Wishaw, United Kingdom, ML2 0DP
Not Yet Recruiting
Research Team
K
Konstantinos Gerasimidis, Professor
CONTACT
S
Sophie F Morris, BSc (Hons)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here